Fred Hutch, Seattle Cancer Care Alliance, and UW Medicine Complete Restructure of Partnership

Learn More

ASH 2021

American Society of Hematology

December 11-14, 2021
In-Person and Virtual Meeting

Follow Fred Hutch at ASH: #ASH21 |  Facebook  |  Twitter

Fred Hutchinson Cancer Research Center’s latest findings on transplantation, cell therapies, precision medicine and more will be featured at the 63nd Annual Meeting and Exposition of the American Society of Hematology (ASH).

This year's annual meeting will be held both in-person at the Georgia World Congress Center in Atlanta, and as a virtual event .

The ASH meeting provides an invaluable educational experience and the latest on the hottest topics in hematology. Attendees include top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.

The meeting features the annual E. Donnall Thomas Lecture, named for the Fred Hutch physician-scientist who was awarded the Nobel Prize in physiology or medicine for his development of bone marrow transplantation. 

Visit the Fred Hutch/Seattle Cancer Care Alliance booth in the Virtual Exhibit Hall.

Saturday-Tuesday, December 11-14, 2021
In-Person in Atlanta, Georgia and Virtual
Contact Information:

Read Our Media Tip Sheet Highlighting Research at ASH

Highlights of Fred Hutch Presentations at ASH

Preclinical Therapeutics Development  |  Clinical Trials  |  Biomarkers, Diagnostics, Prognostics  |  Transplantation Biology  |  COVID-19


Preclinical Therapeutic Development

Oral Presentation: The Combination of Anti-Tigit and Lenalidomide Promotes Synergistic Myeloma-Specific Immunity after ASCT
Abstract No. 328
Presenter: Simone Minnie, Ph.D.
Saturday, Dec. 11, 4 p.m.

Oral Presentation: Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL 
Abstract No. 509
Presenter: Quy Le,  Ph.D.
Sunday, Dec. 12, 4:30 P.M.

Poster Presentation: Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML  
Abstract No. 2788
Presenter: Quy Le, Ph.D.
Sunday, Dec. 12, 6 p.m.

Poster Presentation: Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy
Abstract No. 2776
Presenter: Salvatore Fiorenza, Ph.D.
Sunday, Dec. 12, 6 p.m.

Poster Presentation: Efficient Nanoparticle-Mediated Delivery of Gene Editing Reagents into Human Hematopoietic Stem and Progenitor Cells
Abstract No. 2933
Presenter: Stefan Radtke, Ph.D.
Sunday, Dec. 12, 6 p.m.
Featured in the ASH Poster Walk on Emerging Research in Immunotherapies, Dec. 16, 5-6 p.m.

Clinical Trials

Poster Presentation: Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy
Abstract No. 2816
Presenter: Nicolas Gazeau, Ph.D.
Sunday, Dec. 12, 6 p.m.

Biomarkers, Diagnostics & Prognostics

Oral Presentation: Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions
Abstract No. 802
Presenter Rhonda E. Ries, M.A.
Monday, Dec. 13, 4:30 p.m.

Oral Presentation: Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report
Abstract No. 522
Presenter: Jasmine Naru
Sunday, Dec. 12,  4:30 p.m.

Transplantation Biology

Oral Presentation: Non-Genetic Determinants of Clonotypic T Cell Expansion Following Allogeneic Stem Cell Transplant
Abstract No. 646
Presenter: Albert Yeh, M.D.
Monday, Dec. 13, 10:30 a.m.


Poster Presentation: COVID-19 in Pediatric Hematopoietic Cell Transplant Recipients: A CIBMTR Study
Abstract No. 2868
Presenter: Neel Bhatt, M.B.B.S., M.P.H. 
Saturday, Dec. 12, 6 p.m.

Latest ASH news

All news
Toward better cures for kids with AML: Q&A with Dr. Soheil Meshinchi How researchers are developing personalized therapies for the deadliest childhood leukemia that have fewer side effects November 5, 2021
Q&A: Returning to school, post-transplant As schools reopen for in-person learning, what should bone marrow transplant recipients do? September 30, 2021
Failed Alzheimer’s drug boosts CAR T-cell therapy Engineered immune cells get a helping hand in new clinical trial for multiple myeloma patients September 26, 2019

Contact Our Media Relations Team

For more information or to arrange an interview, please email or call our media relations team.

Last Modified, June 03, 2022